CCR2 antagonism in patients with type 2 diabetes mellitus: A randomized, placebo-controlled study

Diabetes, Obesity and Metabolism

Volumn 16, Issue 11, 2014, Pages 1055-1064

  Di Prospero, N A ^a   Artis, E ^a   Andrade Gordon, P ^b   Johnson, D L ^b   Vaccaro, N ^b   Xi, L ^b   Rothenberg, P ^a  

^a JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^b JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

Antidiabetic drug; Clinical trial; Insulin resistance; Phase I II study; Randomized trial; Type 2 diabetes

Indexed keywords

ALPHA GLUCOSIDASE INHIBITOR; CHEMOKINE RECEPTOR CCR2 ANTAGONIST; GLUCOSE; INSULIN; JNJ 41443532; MEGLITINIDE; METFORMIN; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; PLACEBO; UNCLASSIFIED DRUG; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; AZETIDINE DERIVATIVE; BENZAMIDE DERIVATIVE; CCR2 PROTEIN, HUMAN; CHEMOKINE RECEPTOR CCR2; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; JNJ-41443532;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BODY WEIGHT; CONSTIPATION; CONTROLLED STUDY; DIABETIC PATIENT; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG CONCENTRATION; DRUG DOSE INCREASE; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ECCHYMOSIS; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN RELEASE; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MORNING DOSAGE; MULTICENTER STUDY; MUSCLE STRAIN; NAUSEA; NEUROLOGIC DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; OROPHARYNX PAIN; PARESTHESIA; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SOMNOLENCE; TIME TO MAXIMUM PLASMA CONCENTRATION; UPPER RESPIRATORY TRACT INFECTION; VISUAL DISORDER; XEROSTOMIA; ANTAGONISTS AND INHIBITORS; BODY MASS; CLINICAL TRIAL; DIABETES MELLITUS, TYPE 2; DIET RESTRICTION; DIRECTIVE COUNSELING; DRUG ADMINISTRATION; DRUG EFFECTS; MIDDLE AGED; TREATMENT OUTCOME; UNITED STATES;

ADULT; AZETIDINES; BENZAMIDES; BLOOD GLUCOSE; BODY MASS INDEX; DIABETES MELLITUS, TYPE 2; DIRECTIVE COUNSELING; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FASTING; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; RECEPTORS, CCR2; THIAZOLIDINEDIONES; TREATMENT OUTCOME; UNITED STATES;

EID: 84913543785     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12309     Document Type: Article

References (40)

1. Anderson JW, Kendall CW, Jenkins DJ. Importance of weight management in type 2 diabetes: review with meta-analysis of clinical studies. J Am Coll Nutr 2003; 22: 331-339.
2. Skurk T, Alberti-Huber C, Herder C, Hauner H. Relationship between adipocyte size and adipokine expression and secretion. J Clin Endocrinol Metab 2007; 92: 1023-1033.
3. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993; 259: 87-91.
4. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Jr Ferrante AW. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003; 112: 1796-1808.
5. Xu H, Barnes GT, Yang Q et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 2003; 112: 1821-1830.
6. Wentworth JM, Naselli G, Brown WA et al. Pro-inflammatory CD11c+CD206+ adipose tissue macrophages are associated with insulin resistance in human obesity. Diabetes 2010; 59: 1648-1656.
7. Lumeng CN, Deyoung SM, Bodzin JL, Saltiel AR. Increased inflammatory properties of adipose tissue macrophages recruited during diet-induced obesity. Diabetes 2007; 56: 16-23.
8. Kanda H, Tateya S, Tamori Y et al. MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J Clin Invest 2006; 116: 1494-1505.
9. Lumeng CN, Deyoung SM, Saltiel AR. Macrophages block insulin action in adipocytes by altering expression of signaling and glucose transport proteins. Am J Physiol Endocrinol Metab 2007; 292: E166-E174.
10. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001; 286: 327-334.
11. Spranger J, Kroke A, Mohlig M et al. Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Diabetes 2003; 52: 812-817.
12. Melgarejo E, Medina MA, Sanchez-Jimenez F, Urdiales JL. Monocyte chemoattractant protein-1: a key mediator in inflammatory processes. Int J Biochem Cell Biol 2009; 41: 998-1001.
13. Bruun JM, Lihn AS, Pedersen SB, Richelsen B. Monocyte chemoattractant protein-1 release is higher in visceral than subcutaneous human adipose tissue (AT): implication of macrophages resident in the AT. J Clin Endocrinol Metab 2005; 90: 2282-2289.
14. Sartipy P, Loskutoff DJ. Monocyte chemoattractant protein 1 in obesity and insulin resistance. Proc Natl Acad Sci U S A 2003; 100: 7265-7270.
15. Zeyda M, Farmer D, Todoric J et al. Human adipose tissue macrophages are of an anti-inflammatory phenotype but capable of excessive pro-inflammatory mediator production. Int J Obes (Lond) 2007; 31: 1420-1428.
16. Kamei N, Tobe K, Suzuki R et al. Overexpression of monocyte chemoattractant protein-1 in adipose tissues causes macrophage recruitment and insulin resistance. J Biol Chem 2006; 281: 26602-26614.
17. Tamura Y, Sugimoto M, Murayama T et al. Inhibition of CCR2 ameliorates insulin resistance and hepatic steatosis in db/db mice. Arterioscler Thromb Vasc Biol 2008; 28: 2195-2201.
18. Kang YS, Lee MH, Song HK et al. CCR2 antagonism improves insulin resistance, lipid metabolism, and diabetic nephropathy in type 2 diabetic mice. Kidney Int 2010; 78: 883-894.
19. Tamura Y, Sugimoto M, Murayama T et al. C-C chemokine receptor 2 inhibitor improves diet-induced development of insulin resistance and hepatic steatosis in mice. J Atheroscler Thromb 2010; 17: 219-228.
20. Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes Care 2003; 26: 881-885.
21. Rohlfing CL, Wiedmeyer HM, Little RR, England JD, Tennill A, Goldstein DE. Defining the relationship between plasma glucose and HbA(1c): analysis of glucose profiles and HbA(1c) in the Diabetes Control and Complications Trial. Diabetes Care 2002; 25: 275-278.
22. Goldfine AB, Fonseca V, Jablonski KA et al. The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial. Ann Intern Med 2010; 152: 346-357.
23. Larsen CM, Faulenbach M, Vaag A, Ehses JA, Donath MY, Mandrup-Poulsen T. Sustained effects of interleukin-1 receptor antagonist treatment in type 2 diabetes. Diabetes Care 2009; 32: 1663-1668.
24. Larsen CM, Faulenbach M, Vaag A et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med 2007; 356: 1517-1526.
25. Aronoff S, Rosenblatt S, Braithwaite S, Egan JW, Mathisen AL, Schneider RL. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group. Diabetes Care 2000; 23: 1605-1611.
26. Scherbaum WA, Goke B, German Pioglitazone Study Group. Metabolic efficacy and safety of once-daily pioglitazone monotherapy in patients with type 2 diabetes: a double-blind, placebo-controlled study. Horm Metab Res 2002; 34: 589-595.
27. Goldstein BJ, Cobitz AR, Hand LM, Chen H. Are the metabolic effects of rosiglitazone influenced by baseline glycaemic control? Curr Med Res Opin 2003; 19: 192-199.
28. Faghihimani E, Aminorroaya A, Rezvanian H, Adibi P, Ismail-Beigi F, Amini M. Salsalate improves glycemic control in patients with newly diagnosed type 2 diabetes. Acta Diabetol 2013; 50: 537-543.
29. Koska J, Ortega E, Bunt JC et al. The effect of salsalate on insulin action and glucose tolerance in obese non-diabetic patients: results of a randomised double-blind placebo-controlled study. Diabetologia 2009; 52: 385-393.
30. Rissanen A, Howard CP, Botha J, Thuren T. Effect of anti-IL-1β antibody (canakinumab) on insulin secretion rates in impaired glucose tolerance or type 2 diabetes: results of a randomized, placebo-controlled trial. Diabetes Obes Metab 2012; 14: 1088-1096.
31. Hanefeld M, Schell E, Gouni-Berthold I et al. Orally-administered chemokine receptor CCR2 antagonist CCX140-B in type 2 diabetes: a pilot double-blind, randomized clinical trial. J Diabetes Metab 2012; 3; DOI: 10.4172/2155-6156.1000225.
32. Ehses JA, Perren A, Eppler E et al. Increased number of islet-associated macrophages in type 2 diabetes. Diabetes 2007; 56: 2356-2370.
33. Akash MS, Rehman K, Chen S. Role of inflammatory mechanisms in pathogenesis of type 2 diabetes mellitus. J Cell Biochem 2013; 114: 525-531.
34. Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care 2004; 27: 1487-1495.
35. Matsuda M. Measuring and estimating insulin resistance in clinical and research settings. Nutr Metab Cardiovasc Dis 2010; 20: 79-86.
36. Vergunst CE, Gerlag DM, Lopatinskaya L et al. Modulation of CCR2 in rheumatoid arthritis: a double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum 2008; 58: 1931-1939.
37. Wisniewski T, Bayne E, Flanagan J et al. Assessment of chemokine receptor function on monocytes in whole blood: in vitro and ex vivo evaluations of a CCR2 antagonist. J Immunol Methods 2010; 352: 101-110.
38. Boring L, Gosling J, Cleary M, Charo IF. Decreased lesion formation in CCR2-/- mice reveals a role for chemokines in the initiation of atherosclerosis. Nature 1998; 394: 894-897.
39. Kanamori H, Matsubara T, Mima A et al. Inhibition of MCP-1/CCR2 pathway ameliorates the development of diabetic nephropathy. Biochem Biophys Res Commun 2007; 360: 772-777.
40. Dansereau MA, Gosselin RD, Pohl M et al. Spinal CCL2 pronociceptive action is no longer effective in CCR2 receptor antagonist-treated rats. J Neurochem 2008; 106: 757-769.